What is Mangalam Drugs And Organics Ltd (MANGALAM) share price return in the past 10 years?

Mangalam Drugs And Organics Ltd share price has declined -17.2% annually (CAGR) over the past ten years.

What is the share price of Mangalam Drugs And Organics Ltd (MANGALAM)?

Company share prices are keep on changing according to the market conditions. The current trading price of Mangalam Drugs And Organics Ltd (MANGALAM) on 04-Jun-2026 16:59:59 at 16:59 is 28.70.

What is the P/E ratio of Mangalam Drugs And Organics?

The latest standalone P/E ratio of Mangalam Drugs And Organics as of 04-Jun-2026 is 0.00.

What is the P/B ratio of Mangalam Drugs And Organics Ltd (MANGALAM)?

The latest standalone P/B ratio of Mangalam Drugs And Organics Ltd (MANGALAM) as of 04-Jun-2026 is 0.44.

What is the 52-week high and low of Mangalam Drugs And Organics Ltd (MANGALAM)?

The 52-week high of Mangalam Drugs And Organics Ltd (MANGALAM) is Rs. 94.80 and the 52-week low is Rs. 22.70.

Mangalam Drugs And Organics Ltd (MANGALAM) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Mangalam Drugs And Organics Ltd (MANGALAM)
Brand: Mangalam Drugs And Organics

Key Metrics

Valuation Multiples

Market Cap

₹45 Cr.

Current Price

₹28.7

52-Week Low / High

₹23 / 95

TTM EPS

₹-27.7

TTM Sales

₹232 Cr.

Book Value per Share

₹65.3

P/E Ratio

0.00

Lower than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

0.44

Lower than its 5-year historical median

Price to Sales (P/S)

0.20

Lower than its 5-year historical median

EV/EBITDA

-10.53

Lower than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

4.76%

Underperforms industry median

Return on Capital Employed (ROCE)

8.40%

Underperforms industry median

Return on Assets (ROA)

1.93%

Operating Profit Margin

11.4%

Net Profit Margin

2.18%

Gross Profit Margin

6.7%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-13.66%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

105.98%

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

35.65%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹87 Cr.

Equity

₹15.8 Cr.

Face Value

₹10

All Time Low / High

₹3.43 / 441.50

Mangalam Drugs And Organics stock performance

Key Ratios

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Mangalam Drugs And Organics Ltd a good quality company?

Mangalam Drugs And Organics Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Mangalam Drugs And Organics Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Mangalam Drugs And Organics Ltd vs industry peers?

Mangalam Drugs And Organics Ltd revenue CAGR is 2.42%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Mangalam Drugs And Organics Ltd?

Promoters hold 35.65% of the Mangalam Drugs And Organics Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Valuation ratios of Mangalam Drugs And Organics Ltd vs historical?

The current P/E ratio of 0 is lower than its historical median of 11.73, indicating that the stock is trading below its historical average valuation.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	29.1%	30.2%	25.4%	1.8%	10.7%	28%	18.3%	6.7%	1.2%	8.4%	-
Value Creation Index ⓘ	1.1	1.2	0.8	-0.9	-0.2	1.0	0.3	-0.5	-0.9	-0.4	-
Growth Parameters ⓘ
Sales ⓘ	295	303	279	228	282	385	451	372	369	318	232
Sales YoY Gr.	-	2.7%	-7.8%	-18.5%	24.1%	36.3%	17.3%	-17.5%	-1%	-13.7%	-
Adj EPS ⓘ	11.2	14.5	12.3	-5.1	5.2	17.7	12.4	0.8	-5.7	4.3	-27.7
YoY Gr.	-	29.3%	-15.4%	-141.6%	NA	240.5%	-29.9%	-93.5%	-811.3%	NA	-
BVPS (₹) ⓘ	36.9	54.2	65.6	60.4	65.7	82.6	95.1	96	89.9	93.9	65.3
Adj Net Profit ⓘ	16.2	23	19.4	-8.1	8.2	28	19.6	1.3	-9	6.9	-44
Cash Flow from Ops. ⓘ	21.8	42.8	24.6	21.7	30.6	27.6	25.7	38.1	12.2	42.8	-
Debt/CF from Ops. ⓘ	2.7	1.5	2.8	2.9	1.6	2.3	3.1	2	7.8	2.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	0.9%	2.4%	-11%	-13.7%
Adj EPS ⓘ	-10%	-3.5%	-29.5%	NA
BVPSⓘ	10.9%	7.4%	-0.4%	4.4%
Share Price	-17.2%	-26.7%	-34.9%	-65.1%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	35.5	31.2	20.5	-8.1	8.2	23.8	13.9	0.8	-6.1	4.7	-34.8
Op. Profit Mgn % ⓘ	12.8	15.5	16.8	4.3	8.4	15.1	10.9	6.9	4.7	11.4	-6.1
Net Profit Mgn % ⓘ	5.5	7.6	7	-3.6	2.9	7.3	4.3	0.3	-2.5	2.2	-18.9
Debt to Equity ⓘ	1.1	0.8	0.7	0.7	0.5	0.5	0.5	0.5	0.7	0.6	0.1
Working Cap Days ⓘ	130	114	130	162	136	126	131	192	201	229	122
Cash Conv. Cycle ⓘ	56	58	62	83	47	48	69	95	70	82	-15

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	295.02	302.89	279.38	227.58	282.35	384.70	451.07	372.25	368.59	318.23
Operating Expenses ⓘ +	257.50	256.97	232.53	217.90	258.66	326.68	402.01	346.53	351.22	282.43
Manufacturing Costs	22.38	23.02	29.15	26.60	24.01	30.17	41.99	45.32	50.30	55.25
Material Costs	203.92	195.94	166.77	153.61	195.35	251.96	306.64	250.44	244.51	167.37
Employee Cost	14.39	19.08	22.98	25.82	26.04	29.88	37.25	34.61	39.07	40.59
Other Costs ⓘ	16.81	18.93	13.63	11.87	13.25	14.67	16.14	16.15	17.34	19.23
Operating Profit ⓘ	37.52	45.92	46.85	9.68	23.69	58.02	49.05	25.72	17.38	35.80
Operating Profit Margin (%)	12.7%	15.2%	16.8%	4.3%	8.4%	15.1%	10.9%	6.9%	4.7%	11.3%
Other Income ⓘ +	0.20	0.31	0.84	0.32	1.18	0	0.09	0.44	0.12	0.50
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	9.29	10.04	11.78	8.65	10.40	9.33	11.16	12.96	13.92	14.93
Depreciation ⓘ	4.41	5.01	6.57	7.09	8.22	9.18	10.25	10.99	14.63	16.38
Profit Before Tax ⓘ	24.02	31.18	29.35	-5.74	6.25	39.52	27.73	2.21	-11.06	4.99
Tax ⓘ	7.98	8.91	9.46	2.29	-2	11.55	8.08	0.94	-2.01	-1.93
Profit After Tax	16.03	22.28	19.89	-8.03	8.25	27.97	19.66	1.27	-9.05	6.92
PAT Margin (%)	5.4%	7.4%	7.1%	-3.5%	2.9%	7.3%	4.4%	0.3%	-2.5%	2.2%
Adjusted EPS (₹)	11.2	14.1	12.6	-5.1	5.2	17.7	12.4	0.8	-5.7	4.4
Dividend Payout Ratio (%)	0%	0%	4%	0%	0%	0%	0%	0%	0%	0%

Valuation of Mangalam Drugs&Org. - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	53.04	85.72	103.77	95.66	103.94	130.79	150.56	151.96	142.35	148.66
Share Capital ⓘ	14.38	15.83	15.83	15.83	15.83	15.83	15.83	15.83	15.83	15.83
Reserves ⓘ	38.66	69.89	87.94	79.83	88.11	114.96	134.73	136.13	126.52	132.83
Debt +	52.30	58.17	61.90	59.11	46.03	58.06	72.20	68.33	87.95	81.17
Long Term Debt	16.92	16.85	11.15	8.60	4.17	6.88	25.10	18.77	13.35	9.23
Short Term Debt	35.38	41.32	50.75	50.51	41.86	51.18	47.10	49.57	74.60	71.94
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	20.68	20.78	37.63	32.41	56.59	43.39	54.55	95.43	83.05	91.32
Others Liabilities ⓘ	33.75	24.84	23.50	24.17	24.10	31.87	51.12	42.27	43.79	38.10
Total Liabilities ⓘ	159.76	189.50	226.79	211.36	230.67	264.11	328.43	357.98	357.14	359.24
Fixed Assets
Net Fixed Assets ⓘ +	54.19	92.56	101.91	103.49	101.07	117.82	134.96	142.36	147.31	155.52
Gross Block	97.57	140.26	156.14	165.15	170.92	196.70	223.81	241.40	260.69	280.14
Accumulated Depreciation	43.38	47.70	54.23	61.66	69.85	78.88	88.85	99.04	113.38	124.62
CWIP ⓘ	4.93	0	0.07	0.20	1.24	6.35	5.71	9.49	7.74	2.69
Investments ⓘ	0.24	1.64	0.24	0.24	0.22	0.22	0	0	0.03	0.03
Inventories	47.34	37.25	60.13	73.45	64.84	58.59	117.11	137.47	123.64	138.80
Trade Receivables	30.14	36.82	45.21	17.63	39.98	54.31	46.49	46.53	27.94	39.07
Cash Equivalents	0.50	0.63	0.43	1.43	1.63	0.59	1.95	1.04	1.01	2.57
Others Assets ⓘ	22.43	20.61	18.79	14.91	21.68	26.22	22.20	21.09	49.48	20.54
Total Assets ⓘ	159.76	189.50	226.79	211.36	230.67	264.11	328.43	357.98	357.14	359.24

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	21.81	42.80	24.58	21.69	30.55	27.55	25.71	38.08	12.17	42.76
PBT ⓘ	24.02	31.18	29.35	-5.74	6.25	39.52	27.73	2.21	-11.06	4.99
Adjustment ⓘ	13.85	17.45	18.30	16.22	18.71	17.24	22.37	24.12	27.81	30.37
Changes in Working Capital ⓘ	-12.11	1.5	-16.81	11.21	5.64	-19.94	-15.59	11.72	-4.39	7.49
Tax Paid ⓘ	-3.95	-7.33	-6.26	0	-0.05	-9.27	-8.81	0.03	-0.19	-0.08
Cash Flow From Investing Activity ⓘ +	-10.88	-39.45	-15.95	-9.26	-6.87	-31.29	-27.33	-22.17	-17.91	-19.47
Capex	-10.91	-39.46	-15.98	-9.28	-6.89	-31.29	-27.53	-22.17	-17.88	-19.47
Net Investments	0	-0	0.01	0	0.02	0	0.21	0	-0.03	0
Others ⓘ	0.02	0.02	0.02	0.02	0	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	-11.11	-3.22	-8.82	-11.43	-23.48	2.70	2.98	-16.82	5.70	-21.71
Net Proceeds from Shares ⓘ	0	0.94	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-21.65	-0.07	-5.70	-2.55	-4.42	2.70	18.23	-6.34	-5.41	-4.12
Interest Paid ⓘ	-9.29	-10.04	-11.76	-8.65	-10.40	-9.33	-11.16	-12.96	-13.92	-14.93
Dividend Paid ⓘ	0	0	-0.79	0	0	0	0	0	0	0
Others ⓘ	19.83	5.94	9.43	-0.24	-8.65	9.32	-4.09	2.47	25.03	-2.66
Net Cash Flow ⓘ	-0.18	0.13	-0.20	1	0.20	-1.04	1.36	-0.91	-0.04	1.57

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	38.91	32.11	20.99	-8.05	8.27	23.83	13.97	0.84	-6.15	4.76
ROCE (%)	29.14	30.18	25.35	1.76	10.66	28.01	18.34	6.65	1.23	8.4
Asset Turnover Ratio	1.84	1.79	1.48	1.18	1.42	1.56	1.52	1.08	1.03	0.89
PAT to CFO Conversion(x)	1.36	1.92	1.24	N/A	3.7	0.98	1.31	29.98	N/A	6.18
Working Capital Days
Receivable Days	44.80	39.10	48.70	44.30	33.60	44.70	40.80	45.60	36.90	38.40
Inventory Days	63	49.40	57.80	94.20	80.60	58.60	71.10	124.80	129.30	150.50
Payable Days	67.50	38.60	63.90	83.20	83.20	72.40	58.30	109.30	133.20	190.10

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

18.08

17.58

14.88

10.26

11.01

13.23

34.58

7.09

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Mangalam Drugs And Organics Ltd FAQs

The current trading price of Mangalam Drugs&Org. on 04-Jun-2026 16:59 is ₹28.70.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Mangalam Drugs&Org. stood at ₹45.43 Cr

The latest P/E ratio of Mangalam Drugs&Org. as of 03-Jun-2026 is 0.00.

The latest P/B ratio of Mangalam Drugs&Org. as of 03-Jun-2026 is 0.44.

The 52-week high of Mangalam Drugs&Org. is ₹94.80 and the 52-week low is ₹22.70.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Mangalam Drugs&Org. is ₹232 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Mangalam Drugs And Organics Ltd is a average quality company.

The key valuation ratios of Mangalam Drugs And Organics Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Mangalam Drugs And Organics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Mangalam Drugs And Organics Ltd

Mangalam Drugs & Organics Limited (Mangalam) is a part of the MangalamGroup promoted by Dhoot family in 1972 as Advent Pharma PrivateLimited with a view to set up a plant for manufacture of organic andinorganic chemicals. Mangalam Drugs & Organics commmenced its business in 1977.

The company manufactures chemicals such as API perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates at VAPI-Gujarat State. It has a multi-product manufacturing facility and a in-house Research and Development (R&D) Base.

The Company has a diversified product range having synergies in operations and substantial economies of scale. It is amongst the top three manufacturers in India in almost all the products that it manufactures.

Today Mangalam Drugs & Organics enjoys a very strong brand name in the domestic market. It has over two decades of experience in the industry with a very wide and satisfied customer base.

The company has a state of art multi-product manufacturing facilitiesat Vapi in Gujarat and Sangamner in Maharashtra for production of bulkdrugs perfumery chemicals inorganic chemicals and disperse dyesintermediaries with a strong in-house Research and Development base.

Product range of the company includes:

Active Pharma Ingredients (API)

Anti Malarial
Analgesic / Anti Inflammatory
Diuretic
Anti Hypertensive
Anti Convulsant

API Under Development

Intermediates
Antiurolithic

Prefumery / Specialty Chemicals

Phenyl Ethyl Alcohol
Phenyl Ethyl Methyl Ether
Phenyl Ethyl Acetate

Disperse Dye Intermediates

Meta Nitro Aniline (Mna)(99-09-2)
Meta Amino Propionilide (MAP)
Meta Amino Acetanilide (MAA) (162-28-3)
Para Amino Acetanilide (PAA) 122-80-5)
Para Amino Propionilide (PAP) (59690-89-0)
N-Cyano Ethyl Aniline (1075-76-9)
N,N-BIS (2-Hydroxy Ethyl) Meta Chloro Aniline (Mangalam-1) (92-00-2)
N,N-BIS (2-Acetoxy Ethyl) Meta Chloro Aniline (Mangalam -1A) (26692-46-6) etc.

Achievements/ recognition:

Awarded the ISO 9001:2000 Management System Certificate from DNV for Design Development, Manufacture and supply of Bulk Drugs, and Dyes Intermediates.
Received the WHO GMP Certificate for its Bulk Drug manufacturing Plant

Mangalam Drugs And Organics Ltd (MANGALAM)

Mangalam Drugs And Organics Ltd (MANGALAM)

Mangalam Drugs And Organics stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Mangalam Drugs&Org. - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Mangalam Drugs And Organics Ltd FAQs

About Mangalam Drugs And Organics Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Mangalam Drugs And Organics Ltd (MANGALAM)

Mangalam Drugs And Organics Ltd (MANGALAM)

Mangalam Drugs And Organics stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Mangalam Drugs&Org. - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Mangalam Drugs And Organics Ltd FAQs

What is the share price of Mangalam Drugs&Org.?

What is the market cap of Mangalam Drugs&Org.?

What is the P/E ratio of Mangalam Drugs&Org.?

What is the P/B ratio of Mangalam Drugs&Org.?

What is the 52-week high and low of Mangalam Drugs&Org.?

What is the TTM revenue of Mangalam Drugs&Org.?

Is Mangalam Drugs And Organics Ltd a good quality company?

Is Mangalam Drugs And Organics Ltd undervalued or overvalued?

Is Mangalam Drugs And Organics Ltd a good buy now?

About Mangalam Drugs And Organics Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.